Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2009 Marzo;21(1) > Minerva Biotecnologica 2009 Marzo;21(1):21-30

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

REVIEWS  


Minerva Biotecnologica 2009 Marzo;21(1):21-30

lingua: Inglese

Update on Affibody molecules for in vivo imaging of targets for cancer therapy

Tolmachev V. 1,2,3, Orlova A. 1,2

1 Unit of Biomedical Radiation Sciences, Rudbeck Laboratory Uppsala University, Sweden
2 Affibody AB, Bromma, Sweden
3 Unit of Nuclear Medicine, Department of Medical Sciences Uppsala University, Sweden


FULL TEXT  


An increasing specificity of the cancer treatment requires an accurate detection of cancer-associated molecular targets to avoid over- and undertreatment. Radionuclide molecular imaging is a promising way for visualisation of such targets. Affibody molecules (Affibody® molecules), small (7 kDa) robust scaffold proteins constitute a new promising class of high-affinity molecular probes for in vivo molecular imaging. Pre-clinical studies demonstrated a great potential of derivatives of ZHER2:342 Affibody molecule to visualise expression of HER2 in tumour xenografts. Robustness of the Affibody scaffold enabled labelling in harsh conditions without loosing specificity of the HER2-binding. This paper provides an overview of the recent development of Affibody molecules. During the recent year, an important achievement was the development of site-specific labelling of Affibody molecules providing well-characterised uniform conjugates with defined biodistribution and targeting properties. The site-specific labelling was obtained either by an incorporation of chelators during peptides synthesis of Affibody molecules or by an introduction of a single cysteine in the originally cysteine-free Affibody scaffold and the use of a thiol-directed coupling. A feasibility of modification of the biodistribution of Affibody molecules by different chelators was another interesting finding. This was demonstrated during development of mercaptoacetyl-containing peptide based chelators for 99mTc-labelling of Affibody molecules. Several positron-emitting labels enabled the use of advantages of PET for Affibody-mediated radionuclide imaging. It was demonstrated that the rapid targeting of Affibody molecules is compatible with the use of such labels as 68Ga and 18F.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail